Get the tools and support you need to best manage your eczema

  • This field is for validation purposes and should be left unchanged.

News

… I am a woman surviving it. Who calls into work sick because of eczema? That’s what I’m sure people thought when I was consistently missing work due to lack of sleep, broken and bleeding skin, and sometimes just feeling too emotionally unstable to hold it together in the office. I was doing my best […]

Read More


Understanding AD’s impact to improve your quality of life People living with atopic dermatitis (AD), the most common and chronic form of eczema, know first-hand the burden AD has on both individuals and families. The impacts reach far beyond the serious effects of the disease symptoms such as itch, pain, and inflammation –they also include […]

Read More


Eczema affects more than 30 million people in the United States. The most common and chronic form of eczema is known as atopic dermatitis (AD). There is currently no cure for eczema or AD. To help raise awareness about the serious impact AD has on individuals and families, the National Eczema Association (NEA) has joined […]

Read More


We asked, you answered. The verdict? People living with eczema want more information and more options. This past January, many of you responded to a 6-question online survey to evaluate patient satisfaction and the role of doctors in the treatment of the most serious form of eczema, atopic dermatitis (AD). We learned that the vast majority of […]

Read More


Vice President, Advocacy and Access. Tim will be responsible for development and implementation of key advocacy initiatives that will advance NEA’s mission to improve the quality of life for individuals with eczema through research, support, and education. Tim most recently served as President of Foretop, a consulting firm that provided advocacy and business planning services […]

Read More


June 9, 2016 – On Monday, June 6, 2016 the pharmaceutical companies Regeneron and Sanofi, reported positive results for the Phase 3 the clinical trial of the new biologic drug, dupilumab, when used in conjunction with a topical corticosteroid by adults to treat moderate-to-severe atopic dermatitis (AD).

Read More


May 20, 2016 – Atopic dermatitis (AD) is associated with chronic itch, allergic disease and sleep disturbance, all of which might increase the risk of attention deficit (hyperactivity) disorder (ADD/ADHD).

Read More


May 22, 2016 – Nathan lives in Chicago where he is a medical student. He was diagnosed with eczema at two months old and suffered from severe eczema in grade school and high school. Through treatment, great doctors and avoidance of triggers he has been under control since graduating college.

Read More


May 2, 2016 – In the study, the research team, comprised of veterinary dermatologists, microbiologists, pathologists, and primary scientists, tracked the bacterial populations, or “microbiomes,” on dogs’ skin, and key properties of the skin’s barrier function during an occurrence of AD, and again after standard treatment with antibiotics.

Read More


April 21, 2016 – United States adults with AD have significantly impaired sleep and fatigue affecting IADLs (instrumental activity of daily living), and sleep disturbances may be under-diagnosed in this population.

Read More